Assiut University
aun.edu.egTotal trials
4,663
Capped at 5,000
Active
1,322
Phase 3
218
Total enrollment
15,513,245
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 247 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexmedetomidine | — | 72 | |||||
| Bupivacaine | — | — | 40 | ||||
| Fentanyl | — | — | 17 | ||||
| Dexamethasone | — | — | 31 | ||||
| Ketamine | — | 21 | |||||
| Nalbuphine | — | — | 10 | ||||
| Normal saline | — | 25 | |||||
| MgSO4 | — | — | — | 4 | |||
| dextrose 5% | — | — | — | — | — | 2 | |
| Levobupivacaine | — | — | 11 | ||||
| Propofol | — | — | 11 | ||||
| Bupivacaine 0.5% | — | — | — | 4 | |||
| Methylprednisolone | — | — | — | 4 | |||
| Azithromycin | — | — | — | — | 3 | ||
| Magnesium Sulfate and Bupivacaine 0.125% | — | — | — | — | 3 | ||
| Granisetron | — | — | — | 5 | |||
| Triamcinolone Acetonide | — | — | — | — | 4 | ||
| Hyaluronic Acid | — | — | — | — | 2 | ||
| PCNL | — | — | — | — | — | 1 | |
| vasline | — | — | — | — | — | 1 | |
| B-sitosterol | — | — | — | — | — | 1 | |
| Levobupivacaine + Dexmedetomidine | — | — | — | — | — | 1 | |
| Morphine intrathecal | — | — | — | — | — | 1 | |
| Vitamin E | — | — | — | — | — | 1 | |
| clonidine 1 mg / kg | — | — | — | — | — | 1 | |
| Topical Vancomycin Powder | — | — | — | — | — | 1 | |
| Target Controlled | — | — | — | — | — | 1 | |
| Target Controlled Infusion and lidocaine | — | — | — | — | — | 1 | |
| Mometasone Furoate | — | — | — | — | — | 1 | |
| dexmedetomidine + propofol | — | — | — | — | — | 1 | |
| Propofol alone | — | — | — | — | — | 1 | |
| Lidocaine %2 ampoule | — | — | — | — | — | 1 | |
| Botulinum Toxin-A | — | — | — | — | — | 1 | |
| Tacrolimus | — | — | — | — | — | 1 | |
| Sodium Valproate 500 Mg Prolonged-Release Oral | — | — | — | — | — | 1 | |
| Lamotrigine | — | — | — | — | — | 1 | |
| Bupivacaine with Dexamethasone Solution | — | — | — | — | — | 1 | |
| Nebulization of dexmedetomidine and ketamine | — | — | — | — | — | 1 | |
| Nebulization of dexmedetomidine | — | — | — | — | — | 1 | |
| Minoxidil 5 % | — | — | — | — | — | 1 |
207 more active programs hidden
Next readouts
- 2024-07-15
- 2024-07-20
- 2024-07-30
- 2024-08-01
- 2024-08-13
- 2024-09
- 2024-09-01
- 2024-09-20
- 2024-10-01
- 2024-12
Top conditions
- Postoperative Pain57
- Breast Cancer48
- Rheumatoid Arthritis33
- Inflammatory Bowel Diseases29
- Covid1928
- COVID-1925
- Acute Kidney Injury21
- Systemic Lupus Erythematosus18
Frequently asked questions about Assiut University
- How many clinical trials does Assiut University have on ClinicalTrials.gov?
- Assiut University is listed as the lead sponsor on 4,663 clinical trials in ClinicalTrials.gov, 1,322 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Assiut University's trials are in Phase 3?
- 218 of Assiut University's trials are in Phase 3, spread across 247 active drug programs.
- What therapeutic areas does Assiut University focus on?
- Assiut University's most-studied conditions on ClinicalTrials.gov are Postoperative Pain, Breast Cancer, Rheumatoid Arthritis, Inflammatory Bowel Diseases, Covid19.
- When are Assiut University's next clinical trial readouts?
- Assiut University has 10 upcoming primary-completion readouts tracked here; the soonest is “Intrapleural Nebulization of Bupivacain to Reduce Postoperative Pain”, expected around 2024-07-15.